The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

TARA >
School of Medicine >
Histopathology & Morbid Anatomy >
Histopathology & Morbid Anatomy (Scholarly Publications) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2262/53767

Title: B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
Author: FINN, STEPHEN
Sponsor: 
Name Grant Number
CA130895

Author's Homepage: http://people.tcd.ie/finns
Keywords: Oncology
papillary thyroid carcinoma (PTC)
B-Raf(V600E)
Issue Date: 2010
Citation: Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S, B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression., Proceedings of the National Academy of Sciences of the United States of America, 107, 23, 2010, 10649-54
Series/Report no.: Proceedings of the National Academy of Sciences of the United States of America
107
23
Abstract: Although B-Raf(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressiveness is not fully understood. Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs. An independent cohort of B-Raf(V600E)-positive PTCs showed significantly higher expression levels of many extracellular matrix genes compared with controls. We performed extensive in vitro and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously shown to be important in the regulation of tumor angiogenesis and metastasis and is present in abundance in tumor stroma. Knockdown of B-Raf(V600E) resulted in TSP-1 down-regulation and a reduction of adhesion and migration/invasion of human thyroid cancer cells. Knockdown of TSP-1 resulted in a similar phenotype. B-Raf(V600E) cells in which either B-Raf(V600E) or TSP-1 were knocked down were implanted orthotopically into the thyroids of immunocompromised mice, resulting in significant reduction in tumor size and fewer pulmonary metastases from the primary carcinoma as compared with the control cells. Treatment of orthotopic thyroid tumors, initiated 1 week after tumor cell implantation with PLX4720, an orally available selective inhibitor of B-Raf(V600E), caused a significant tumor growth delay and decreased distant metastases, without evidence of toxicity. In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis. Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
Description: PUBLISHED
URI: http://hdl.handle.net/2262/53767
Related links: http://dx.crossref.org/10.1073%2Fpnas.1004934107
Appears in Collections:Histopathology & Morbid Anatomy (Scholarly Publications)

Files in This Item:

File Description SizeFormat
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.pdfPublished (publisher's copy) - Peer Reviewed1.12 MBAdobe PDFView/Open


This item is protected by original copyright


Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback